Accepted for Publication: June 21, 2014.
Published Online: August 13, 2014. doi:10.1001/jamadermatol.2014.1939.
Study concept and design: Ellebrecht, Allman, Tsai, Goldenberg, Payne.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Ellebrecht, Tsai, Wegener, Goldenberg, Payne.
Critical revision of the manuscript for important intellectual content: Ellebrecht, Choi, Allman, Goldenberg, Payne.
Statistical analysis: Ellebrecht.
Obtained funding: Payne.
Administrative, technical, or material support: Ellebrecht, Choi, Allman, Wegener, Goldenberg, Payne.
Study supervision: Allman, Tsai, Payne.
Conflict of Interest Disclosures: Drs Wegener and Goldenberg are employed by and hold equity ownership of Immunomedics Inc, the manufacturer of veltuzumab. Drs Allman and Payne receive grant funding from the National Institutes of Health for research unrelated to the reported study. No other disclosures were reported.
Funding/Support: This study was supported in part by the Penn Institute for Immunology (Drs Allman and Payne), Deutsche Forschungsgemeinschaft (grant EL711/1-1 to Dr Ellebrecht), and Immunomedics Inc, who provided the study drug and performed serum pharmacokinetic and human anti-veltuzumab antibody analyses.
Role of the Sponsor: Penn Institute for Immunology, Deutsche Forschungsgemeinschaft, and Immunomedics Inc had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Heather Horne, AS, and Kirill Gordeyev, MS, both with Immunomedics, Inc, and Cynthia Clark, PhD, MSN, Perelman School of Medicine, University of Pennsylvania, provided administrative, technical, and/or regulatory assistance. No financial compensation was given.